Arrowhead Pharmaceuticals reports advances in genetic therapies for liver disease and Hepatitis B


Arrowhead Pharmaceuticals has released a flurry of press releases related to their genetic therapy approaches. Here is a quick summary of what we have seen.

Arrowhead’s ARO-HBV, a third generation RNA interference therapy for Hepatitis B, presented promising results at the 2019 International Liver Congress in a Phase 1/2 clinical study.

The therapy was shown to rapidly reduce Hepatitis B surface antigen HBsAg in patients who met the diagnostic threshold for having Hepatitis B for at least 24 weeks. The therapy was well tolerated and the side effects reported were related to injection site inflammation/irritation.

Arrowhead has also entered a partnership with Janssen Pharmaceuticals, Inc, a subsidiary of Johnson & Johnson to help develop & commercialize the product.

Source: Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™

In a long term clinical trial, Arrowhead’s RNAi therapy has shown reversal of Alpha-1 Liver disease. The therapy demonstrated sustained reduction of mutant Z-AAT protein expression, which had the effect of not only preventing future damage to the liver, but reversing damage that had already been done. The therapy ( ARO-AAT ) received clearance by the FDA to begin phase 2 and 3 trials, shortly after the positive result was reported.

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

Arrowhead Preclinical Data Demonstrates RNAi Therapy Prevents and Reverses Alpha-1 Liver Disease at


Please enter your comment!
Please enter your name here